165 related articles for article (PubMed ID: 34882988)
1. Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease.
Chan Ng PLP; Mopur A; Goh DYT; Ramamurthy MB; Lim MTC; Lim LK; Ooi PL; Ang EY
Int J Rheum Dis; 2022 Feb; 25(2):228-231. PubMed ID: 34882988
[TBL] [Abstract][Full Text] [Related]
2. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature.
Yamazaki S; Shimizu M; Yakabe A; Inage E; Jimbo K; Suzuki M; Miyaoka F; Kaneko S; Irabu H; Shimbo A; Ohtomo Y; Mori M; Morio T; Shimizu T
Immunol Med; 2024 Jun; 47(2):110-117. PubMed ID: 38557269
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases.
Wendel S; Venhoff N; Frye BC; May AM; Agarwal P; Rizzi M; Voll RE; Thiel J
J Autoimmun; 2019 Jun; 100():131-136. PubMed ID: 30862449
[TBL] [Abstract][Full Text] [Related]
5. Cardiac involvement in a case of juvenile dermatomyositis with positive anti-melanoma differentiation associated protein 5 antibody.
Kaplan MM; Çelikel E; Güngörer V; Ekici Tekin Z; Gürsu HA; Polat SE; Cinel G; Çelikel Acar B
Int J Rheum Dis; 2023 Aug; 26(8):1582-1585. PubMed ID: 36852875
[TBL] [Abstract][Full Text] [Related]
6. Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies.
Ohmura SI; Yamabe T; Naniwa T
Mod Rheumatol Case Rep; 2021 Jan; 5(1):76-81. PubMed ID: 32867615
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report.
Yen TH; Tseng CW; Wang KL; Fu PK
Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946303
[TBL] [Abstract][Full Text] [Related]
8. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
[TBL] [Abstract][Full Text] [Related]
9. Case report: Successful treatment of anti-MDA5-positive to negative dermatomyositis-associated interstitial lung disease with the JAK inhibitor tofacitinib.
Jiang Z; Yao X; Tang F; Ma W
Immun Inflamm Dis; 2023 Jun; 11(6):e897. PubMed ID: 37382261
[TBL] [Abstract][Full Text] [Related]
10. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.
Yu Z; Wang L; Quan M; Zhang T; Song H
Rheumatology (Oxford); 2021 Apr; 60(4):1700-1707. PubMed ID: 33024992
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.
Chen Z; Wang X; Ye S
N Engl J Med; 2019 Jul; 381(3):291-293. PubMed ID: 31314977
[No Abstract] [Full Text] [Related]
12. Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients.
Xue Y; Zhang J; Deng J; Kuang W; Wang J; Tan X; Li C; Li S; Li C
Ann Rheum Dis; 2023 Nov; 82(11):1499-1501. PubMed ID: 37280048
[No Abstract] [Full Text] [Related]
13. Anti-MDA5-associated dermatomyositis.
Gupta R; Kumar S; Gow P; Hsien-Cheng Chang L; Yen L
Intern Med J; 2020 Apr; 50(4):484-487. PubMed ID: 32270621
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.
Kurasawa K; Arai S; Namiki Y; Tanaka A; Takamura Y; Owada T; Arima M; Maezawa R
Rheumatology (Oxford); 2018 Dec; 57(12):2114-2119. PubMed ID: 30060040
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis.
Takatani A; Koga T; Fujita Y; Fukui S; Endo Y; Shimizu T; Kawakami A
Clin Immunol; 2020 Jun; 215():108451. PubMed ID: 32360518
[No Abstract] [Full Text] [Related]
16. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
[No Abstract] [Full Text] [Related]
17. Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China.
Zhang J; Sun L; Shi X; Li S; Liu C; Li X; Lu M; Deng J; Tan X; Guan W; Li G; Wen X; Liu P; Li C
Arthritis Res Ther; 2023 Oct; 25(1):204. PubMed ID: 37853451
[TBL] [Abstract][Full Text] [Related]
18. Rapid and sustained response to JAK inhibition in a child with severe MDA5 + juvenile dermatomyositis.
Strauss T; Günther C; Schnabel A; Wolf C; Hahn G; Lee-Kirsch MA; Brück N
Pediatr Rheumatol Online J; 2023 Sep; 21(1):104. PubMed ID: 37726751
[TBL] [Abstract][Full Text] [Related]
19. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.
Wu W; Guo L; Fu Y; Wang K; Zhang D; Xu W; Chen Z; Ye S
Clin Rev Allergy Immunol; 2021 Apr; 60(2):293-304. PubMed ID: 33405101
[TBL] [Abstract][Full Text] [Related]
20. Lung infection or inflammation-a puzzling case of MDA-5 associated juvenile dermatomyositis.
Vuppala A; Sondhi M; Umer S
Pediatr Rheumatol Online J; 2023 Dec; 21(1):147. PubMed ID: 38124190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
